Rates of Treatment Discontinuation Due to Adverse Events for EchinocandinsAuthors' Reply
- 16 June 2011
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (7) , 3643-3644
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Systematic Review and Meta-Analysis of the Tolerability and Hepatotoxicity of Antifungals in Empirical and Definitive Therapy for Invasive Fungal InfectionAntimicrobial Agents and Chemotherapy, 2010
- Reporting of Safety Results in Published Reports of Randomized Controlled TrialsArchives of internal medicine (1960), 2009
- Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive CandidiasisClinical Infectious Diseases, 2007
- Anidulafungin versus Fluconazole for Invasive CandidiasisNew England Journal of Medicine, 2007
- Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trialThe Lancet, 2007
- Comparison of echinocandin antifungalsTherapeutics and Clinical Risk Management, 2007
- Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT StatementAnnals of Internal Medicine, 2004
- Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and NeutropeniaNew England Journal of Medicine, 2004
- Phase 2, Randomized, Dose-Ranging Study Evaluating the Safety and Efficacy of Anidulafungin in Invasive Candidiasis and CandidemiaAntimicrobial Agents and Chemotherapy, 2004
- Comparison of Caspofungin and Amphotericin B for Invasive CandidiasisNew England Journal of Medicine, 2002